

Davidson, Mark

From: Davidson, Mark
Sent: Tuesday, June 20, 2017 11:53 AM
To: 'Rizwana Sproule'
Cc: 'Alex Babayan'; 'Nadia Agopyan'
Subject: Kite Pharma BLA 125643 Clinical Information Request 6.20.17
Attachments: BLA 125643.Clinical IR 6.20.17.pdf

Importance: High

Dear Dr. Sproule,

We have the attached Clinical request for Information:

Please respond by Wednesday, June 28, 2017.

Mark L. Davidson, RHIA
Regulatory Project Manager
OTAT/CBER/FDA
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002
Phone: 240-402-8277
Fax:301-595-1303
mark.davidson@fda.hhs.gov

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone."